From my (bad) experience with P3 trials, companies have been only too willing to paint a positive 'bread crumb' picture which has eventually translated into failure.
So, does our lack of blatant positive spin (emanating from Acadia) suggest that all is good? After all, if they are aiming at a low ball takeover, why provide (or allow) Neuren to pump results.
To much second guessing to attempt any sort of predictive analysis.
I guess it is just a matter of keeping the faith or losing it. [Me, I'll be hanging on.]
TROFINETIDE TRIALS UPDATE, page-78
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.34 |
Change
-0.410(2.60%) |
Mkt cap ! $1.960B | |||
| Open | High | Low | Value | Volume |
| $15.88 | $15.93 | $15.34 | $6.463M | 415.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6044 | $15.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.57 | 1411 | 2 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |